GLSI - Greenwich LifeSciences, Inc.
9.38
-0.480 -5.117%
Share volume: 48,139
Last Updated: 05-06-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.13%
PREVIOUS CLOSE
CHG
CHG%
$9.86
-0.48
-0.05%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | |
|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 05-20-2024 | 08-14-2024 | 11-14-2024 | |
| Total revenue | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | |||
| Operating expenses | 2.537 M | 2.661 M | 2.729 M | |
| Selling general and admin | 342.688 K | 353.531 K | 437.011 K | |
| Research and development | 2.195 M | 2.308 M | 2.292 M | |
| Total expenses | 2.537 M | 2.661 M | 2.729 M | |
| 4.90% | 2.54% | |||
| Operating income | -2.537 M | -2.661 M | -2.729 M | |
| Ebit | -2.537 M | -2.661 M | -2.729 M | |
| Pretax income | -2.473 M | -2.607 M | -2.669 M | |
| 5.40% | 2.38% | |||
| Income tax | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | |
| Net income | -2.473 M | -2.607 M | -2.669 M | |
| -5.40% | -2.38% |
